CRISPR-NSID: an in vivo CRISPR/Cas9 negative selection screen reveals EZH2 as a druggable dependency factor in a genetic desmoid tumor model
Authors
Thomas Naert,
Tom NieuwenhuysenSuzan Demuynck,
Sven Grande,
Joanna Przybyl,
Marnik Vuylsteke,
Rivka Noelanders,
Dieter Tulkens,
Dionysia Dimitrakopoulou,
David Creytens,
Matt Rijn,
Savvas Savvides,
Kris Vleminckx,
Joanna Przybył,
Mushriq Jazrawe,
Benjamin Alman,
Paul Coucke,
Kim Leeneer +16 authors
,
Christian Vanhove Tip Tip